{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:24:25Z","timestamp":1785583465764,"version":"3.56.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Stavudine (D4T), zidovudine (AZT), and tenofovir (TDF) along with lamivudine (3TC) are the most widely used HIV treatment regimens in China. China's National Free Antiretroviral Treatment Programme (NFATP) has replaced D4T with AZT or TDF in the standard first-line regimens since 2010. Few studies have evaluated the adherence, virological outcome, and drug resistance in HIV patients receiving first-line antiretroviral therapy (ART) from 2011 to 2015 due to changes in ART regimen.<\/jats:p>\n            <jats:p>From 2011 to 2015, 2787 HIV patients were examined, with 364, 1453, and 970 patients having initiated D4T-, AZT-, and TDF-based first-line ART regimens, respectively. The Cochran\u2013Armitage test was used to examine the trends in clinical and virological outcomes during 2011 to 2015. Logistic regression was used to examine the effects of different regimens after 9 to 24 months of ART.<\/jats:p>\n            <jats:p>From 2011 to 2014\u20132015, adverse drug reactions decreased from 18.9% to 6.7%, missed doses decreased from 9.9% to 4.6%, virological failure decreased from 16.2% to 6.4%, and drug resistance rates also significantly decreased from 5.4% to 1.1%. These successes were strongly associated with the standardized use of TDF- or AZT-based regimens in place of the D4T-based regimen. Poor adherence decreased from 11.3% in patients who initiated D4T-based regimens to 4.9% in those who initiated TDF-based regimens, adverse drug reactions decreased from 32.4% to 6.7%, virological failure reduced from 18.7% to 8.6%, and drug resistance reduced from 5.8% to 2.9%. Compared with patients who initiated AZT-based regimens, patients who initiated TDF-based regiments showed significant reductions in adherence issues, adverse drug reactions, virological outcomes, and drug resistance. Significant differences were also observed between those who initiated D4T- and AZT-based regimens.<\/jats:p>\n            <jats:p>The good control of HIV replication and drug resistance was attributed to the success of China's NFATP from 2011 to 2015. This study provided real world evidence for further scaling up ART and minimizing the emergence of drug resistance in the \u201cThree 90\u201d era.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013555","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T02:51:23Z","timestamp":1544842283000},"page":"e13555","source":"Crossref","is-referenced-by-count":20,"title":["Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015"],"prefix":"10.1097","volume":"97","author":[{"given":"Pengtao","family":"Liu","sequence":"first","affiliation":[{"name":"Weifang Medical University, Weifang, Shandong Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjie","family":"Liao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbao","family":"Zuo","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebing","family":"Leng","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Kan","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"You","sequence":"additional","affiliation":[{"name":"Weifang Medical University, Weifang, Shandong Province"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xing","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Ruan","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"},{"name":"Guangxi Center for Disease Control and Prevention, Nanning, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Shao","sequence":"additional","affiliation":[{"name":"State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS\/STD Control and Prevention (NCAIDS), Chinese Center for Disease Control and Prevention (China CDC), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing"},{"name":"Guangxi Center for Disease Control and Prevention, Nanning, P. R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1093\/jac\/dkv078","article-title":"Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12","volume":"70","author":"Xing","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R2-20230914","first-page":"1","article-title":"Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7448\/IAS.19.1.20798","article-title":"Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya","volume":"19","author":"Brooks","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1086\/649884","article-title":"Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India","volume":"50","author":"Bender","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S0140-6736(12)61038-1","article-title":"Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis","volume":"380","author":"Gupta","year":"2012","journal-title":"Lancet"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bjid.2016.11.009","article-title":"Trends and predictors of HIV-1 acquired drug resistance in Minas Gerais, Brazil: 2002-2012","volume":"21","author":"Duani","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1086\/649215","article-title":"Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China","volume":"50","author":"Ma","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-14-322","article-title":"Improved virologic outcomes over time for HIV-infected patients on antiretroviral therapy in a cohort from Rio de Janeiro, 1997\u20132011","volume":"14","author":"Martin","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-10105-7","article-title":"Prognosis of HIV patients receiving antiretroviral therapy according to CD4 counts: a long-term follow-up study in Yunnan, China","volume":"7","author":"Ren","year":"2017","journal-title":"Sci Rep"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkv500","article-title":"Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance","volume":"71","author":"Rowley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3350\/cmh.2015.0053","article-title":"The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy","volume":"22","author":"Kim","year":"2016","journal-title":"Clin Mol Hepatol"},{"key":"R13-20230914","first-page":"1","article-title":"Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort study","volume":"7","author":"Tang","year":"2017","journal-title":"Sci Rep"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/157016211795569122","article-title":"Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China","volume":"9","author":"Wang","year":"2011","journal-title":"Curr HIV Res"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"e62408","DOI":"10.1371\/journal.pone.0062408","article-title":"Incidence and associated factors of HIV drug resistance in Chinese HIV-infected patients receiving antiretroviral treatment","volume":"8","author":"Xing","year":"2013","journal-title":"PLoS ONE"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"e0166661","DOI":"10.1371\/journal.pone.0166661","article-title":"Drug resistance and virological failure among HIV-infected patients after a decade of antiretroviral treatment expansion in eight provinces of China","volume":"11","author":"Zuo","year":"2016","journal-title":"PLoS ONE"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1473-3099(11)70097-4","article-title":"Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study","volume":"11","author":"Zhang","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-151-4-200908180-00006","article-title":"Five-year outcomes of the China National Free Antiretroviral Treatment Program","volume":"151","author":"Zhang","year":"2009","journal-title":"Ann Intern Med"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.meegid.2016.08.031","article-title":"HIV-1 drug resistance and resistance testing","volume":"46","author":"Clutter","year":"2016","journal-title":"Infect Genet Evol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1086\/368314","article-title":"Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus","volume":"36","author":"Karras","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1473-3099(14)70946-6","article-title":"HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010\u201312: a retrospective observational cohort study","volume":"14","author":"Zhang","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/2325957416686190","article-title":"Zidovudine - versus tenofovir-based antiretroviral therapy for the initial treatment of HIV infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China","volume":"16","author":"Cheung","year":"2017","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect Dis"},{"issue":"(suppl 2)","key":"R29-20230914","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1093\/infdis\/jit112","article-title":"Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy\u2014implications for sustained efficacy of ART in resource-limited settings","volume":"207","author":"Hill","year":"2013","journal-title":"J Infect Dis"},{"issue":"(suppl 2)","key":"R30-20230914","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/infdis\/jit109","article-title":"Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries","volume":"207","author":"De Luca","year":"2013","journal-title":"J Infect Dis"},{"key":"R31-20230914","first-page":"17","article-title":"Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world","volume":"14","author":"Frentz","year":"2012","journal-title":"AIDS Rev"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"e64459","DOI":"10.1371\/journal.pone.0064459","article-title":"Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study","volume":"8","author":"Velen","year":"2013","journal-title":"PLoS ONE"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/trstmh\/trv016","article-title":"Toxicity and clinical outcomes in patients with HIV on zidovudine and tenofovir based regimens: a retrospective cohort study","volume":"109","author":"Thuppal","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R34-20230914","first-page":"1","article-title":"Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria","volume":"12","author":"Eluwa","year":"2012","journal-title":"BMC Clin Pharmacol"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(11)70248-1","article-title":"Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study","volume":"12","author":"Costagliola","year":"2012","journal-title":"Lancet Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812140-00054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:03:21Z","timestamp":1694725401000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812140-00054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":30,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013555","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}